Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

BACKGROUND: The amyloid-beta peptide Abeta(42) has been implicated in the pathogenesis of Alzheimer's disease (AD). We aimed to test the effects of tarenflurbil, a selective Abeta(42)-lowering agent (SALA), on cognition and function in patients with mild to moderate AD. METHODS: 210 patients li...

Descrición completa

Detalles Bibliográficos
Main Authors: Wilcock, G, Black, SE, Hendrix, S, Zavitz, K, Swabb, E, Laughlin, M
Formato: Journal article
Idioma:English
Publicado: 2008